ABSTRACT:
The MIC
90
of RBx 14255, a novel ketolide, against
Clostridium difficile
was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An
in vitro
time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for
C. difficile
. Furthermore, in the hamster model of
C. difficile
infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for
C. difficile
treatment.